GLP-1 Drugs for Diabetes: New Perspectives on Blood Sugar and Weight Control
Review of GLP-1 agonist new perspectives in T2D covers updated glycemic and weight management evidence, emerging formulations, and expanded indications.
Quick Facts
What This Study Found
Review of GLP-1 agonist new perspectives in T2D covers updated glycemic and weight management evidence, emerging formulations, and expanded indications.
Key Numbers
Obesity affects 988 million people and T2DM 537 million globally, with figures continuously increasing.
How They Did This
Methodology in publication.
Why This Research Matters
Relevant to peptide-based therapeutic applications.
The Bigger Picture
Contributes to peptide therapeutic evidence.
What This Study Doesn't Tell Us
Limitations in publication.
Questions This Raises
- ?Long-term implications?
- ?Comparison to evidence?
- ?Next research?
Trust & Context
- Key Stat:
- Key finding Review of GLP-1 agonist new perspectives in T2D covers updated glycemic and weight management eviden
- Evidence Grade:
- Based on study design.
- Study Age:
- Published in 2025.
- Original Title:
- GLP-1 agonists in glycemic and weight control of type 2 diabetes. New perspectives.
- Published In:
- Medicina clinica, 165(3), 107042 (2025)
- Database ID:
- RPEP-09894
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What does this mean?
Review of GLP-1 agonist new perspectives in T2D covers updated glycemic and weight management evidence, emerging formulations, and expanded indications.
How reliable?
Consult publication and provider.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09894APA
Alonso, Silvia Patricia; Valdes, Sergio; Doulatram-Gamgaram, Viyey Kishore. (2025). GLP-1 agonists in glycemic and weight control of type 2 diabetes. New perspectives.. Medicina clinica, 165(3), 107042. https://doi.org/10.1016/j.medcli.2025.107042
MLA
Alonso, Silvia Patricia, et al. "GLP-1 agonists in glycemic and weight control of type 2 diabetes. New perspectives.." Medicina clinica, 2025. https://doi.org/10.1016/j.medcli.2025.107042
RethinkPeptides
RethinkPeptides Research Database. "GLP-1 agonists in glycemic and weight control of type 2 diab..." RPEP-09894. Retrieved from https://rethinkpeptides.com/research/alonso-2025-glp1-agonists-in-glycemic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.